Pan Daniel, Martin Christopher A, Nazareth Joshua, Sze Shirley, Al-Oraibi Amani, Gogoi Mayuri, Grolmusova Natalia, Divall Pip, Decker Jonathan, Fletcher Eve, Williams Caroline, Hay James, Baggaley Rebecca F, Wyllie Anne L, Stephenson Iain, Gaillard Erol, Nellums Laura B, Clark Tristan William, Van-Tam Jonathan Nguyen, Cowling Benjamin J, Hollingsworth T Déirdre, Gray Laura, Barer Michael, Pareek Manish
Development Centre for Population Health, University of Leicester, Leicester, UK.
Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.
BMJ Open. 2024 Dec 2;14(12):e085127. doi: 10.1136/bmjopen-2024-085127.
Understanding how RNA viral load changes (viral load kinetics) during acute infection in SARS-CoV-2 can help to identify when and which patients are most infectious. We seek to summarise existing data on the longitudinal RNA viral load kinetics of SARS-CoV-2 sampled from different parts of the respiratory tract (nose, nasopharynx, oropharynx, saliva and exhaled breath) and how this may vary with age, sex, ethnicity, immune status, disease severity, vaccination, treatment and virus variant.
We will conduct a systematic review and meta-analysis, using studies identified through MEDLINE and EMBASE (via Ovid). All research studies reporting primary data on longitudinal RNA viral load kinetics of infected patients with SARS-CoV-2 will be included. Methodological quality will be assessed using a validated checklist for longitudinal studies as well as predefined quality criteria for assessment of individual-level RNA viral load. Should the data allow, we will aim to perform individual patient-level meta-analysis. Our primary outcomes are duration to, and quantity of peak RNA viral load, and total duration of viral load shedding within different respiratory compartments. Secondary outcomes include duration of lateral flow antigen and virus culture positivity and variation of RNA viral load by age, immune status, disease severity, vaccination, treatment, lateral flow tests, viral culture positivity and SARS-CoV-2 variant. Study-level effects affecting observations, but not related to properties of the patient, such as the PCR platform and gene target will also be recorded. Random-effects models will estimate the population mean and individual-level variation in viral shedding conditional on the aforementioned variables. Finally, we will summarise the key mechanistic models used in the literature to reconstruct individual-level viral kinetics and estimate how different factors shape viral dynamics over time.
Ethical approval is not needed as data will be obtained from published articles or studies with data that have already received and ethical review for analysis. Manuscript(s) will be prepared for publication.
PROSPERO ID: CRD42023385315.
了解严重急性呼吸综合征冠状病毒2(SARS-CoV-2)急性感染期间RNA病毒载量如何变化(病毒载量动力学)有助于确定何时以及哪些患者传染性最强。我们旨在总结从呼吸道不同部位(鼻腔、鼻咽、口咽、唾液和呼出气体)采集的SARS-CoV-2纵向RNA病毒载量动力学的现有数据,以及这如何随年龄、性别、种族、免疫状态、疾病严重程度、疫苗接种、治疗和病毒变体而变化。
我们将进行一项系统评价和荟萃分析,使用通过MEDLINE和EMBASE(通过Ovid)检索到的研究。所有报告SARS-CoV-2感染患者纵向RNA病毒载量动力学原始数据的研究都将被纳入。将使用经过验证的纵向研究清单以及评估个体水平RNA病毒载量的预定义质量标准来评估方法学质量。如果数据允许,我们的目标是进行个体患者水平的荟萃分析。我们的主要结局是达到RNA病毒载量峰值的持续时间和峰值数量,以及不同呼吸道区域内病毒载量排出的总持续时间。次要结局包括侧向流动抗原和病毒培养阳性的持续时间,以及RNA病毒载量随年龄、免疫状态、疾病严重程度、疫苗接种、治疗、侧向流动检测、病毒培养阳性和SARS-CoV-2变体的变化。还将记录影响观察结果但与患者属性无关的研究水平效应,例如PCR平台和基因靶点。随机效应模型将根据上述变量估计病毒排出的总体均值和个体水平变异。最后,我们将总结文献中用于重建个体水平病毒动力学的关键机制模型,并估计不同因素如何随时间塑造病毒动态。
由于数据将从已发表的文章或已接受伦理审查以进行分析的数据研究中获取,因此无需伦理批准。将准备稿件以供发表。
PROSPERO标识符:CRD42023385315。